A randomized, double blind, placebo controlled, clinical study to evaluate the efficacy and safety of Curcuma caesia for weight management in obesity.

Sami Labs Limited0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1 Intake of over the counter weight loss agents, centrally acting appetite suppressants in the previous six months.
•2 Pathophysiologic/ genetic syndromes associated with obesity (Cushingâ??s syndrome, Turnerâ??s syndrome, Praderwilli syndrome).
•3 Patients with evidence of malignancy.
•4 Patients on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergic, etc. or any other drugs that may have an influence on the outcome of the study.
•5 Symptomatic patient with clinical evidence of Heart failure.
•6 History of HIV and other viral infections.
•7 Prior surgical therapy for obesity
•8 History of hypersensitivity to any of the herbal extracts or dietary supplement.
•9 Pregnant / lactating woman.
•10 Patients who have completed participation in any other clinical trial during the past six (06) months.
•11 Any other condition which the Principal Investigator thinks may jeopardize the study.

发起方

Sami Labs Limited